A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris

Background: Oral isotretinoin is highly effective in all forms and grades of acne, even in lower dosages (<0.5 mg/kg/day). There is a paucity of comparative data on the various low-dose regimens of oral isotretinoin in the Indian literature. Objectives: To assess and compare the efficacy and tole...

Full description

Bibliographic Details
Main Authors: Daulat Ram Dhaked, Ram Singh Meena, Anshul Maheshwari, Uma Shankar Agarwal, Saroj Purohit
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Indian Dermatology Online Journal
Subjects:
Online Access:http://www.idoj.in/article.asp?issn=2229-5178;year=2016;volume=7;issue=5;spage=378;epage=385;aulast=Dhaked
id doaj-9ee77efc295d4604b529b4b0c1e09c2c
record_format Article
spelling doaj-9ee77efc295d4604b529b4b0c1e09c2c2020-11-24T21:07:10ZengWolters Kluwer Medknow PublicationsIndian Dermatology Online Journal2229-51782016-01-017537838510.4103/2229-5178.190505A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgarisDaulat Ram DhakedRam Singh MeenaAnshul MaheshwariUma Shankar AgarwalSaroj PurohitBackground: Oral isotretinoin is highly effective in all forms and grades of acne, even in lower dosages (<0.5 mg/kg/day). There is a paucity of comparative data on the various low-dose regimens of oral isotretinoin in the Indian literature. Objectives: To assess and compare the efficacy and tolerability of two low-dose oral isotretinoin treatment regimens (20 mg daily and 20 mg alternate days) in moderate to severe acne vulgaris. Materials and Methods: A total of 240 patients with moderate to severe acne vulgaris were selected and randomized into two groups and treated with a fixed dose of 20 mg of isotretinoin (Group A - daily and Group B - alternate days) for 24 weeks and followed up for 12 weeks post therapy. Results: A total of 234 patients completed the study. At the end of therapy, decrease in the total acne loads up to 98.99% (Group A) and 97.69% (Group B) was achieved from the baseline (P < 0.01), excellent response was observed in 98.3% (Group A) and 93.96% (Group B) patients (P = 0.166). In the severe acne, Group A performed significantly better than Group B until the end of 36 weeks. While in the moderate acne, significant difference in the response between both groups was observed only up to 12 weeks. No serious side effect was observed. Conclusion: Both isotretinoin regimens were well tolerated and found to be an effective treatment for moderate to severe acne vulgaris. However, in moderate acne 20 mg alternate day regimen may be preferred. A 20 mg daily regimen is a better choice for severe acne in terms of response. Limitation: Small sample size and short follow-up period.http://www.idoj.in/article.asp?issn=2229-5178;year=2016;volume=7;issue=5;spage=378;epage=385;aulast=DhakedAcne vulgarisfixed doselow-dose isotretinoin
collection DOAJ
language English
format Article
sources DOAJ
author Daulat Ram Dhaked
Ram Singh Meena
Anshul Maheshwari
Uma Shankar Agarwal
Saroj Purohit
spellingShingle Daulat Ram Dhaked
Ram Singh Meena
Anshul Maheshwari
Uma Shankar Agarwal
Saroj Purohit
A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris
Indian Dermatology Online Journal
Acne vulgaris
fixed dose
low-dose isotretinoin
author_facet Daulat Ram Dhaked
Ram Singh Meena
Anshul Maheshwari
Uma Shankar Agarwal
Saroj Purohit
author_sort Daulat Ram Dhaked
title A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris
title_short A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris
title_full A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris
title_fullStr A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris
title_full_unstemmed A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris
title_sort randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris
publisher Wolters Kluwer Medknow Publications
series Indian Dermatology Online Journal
issn 2229-5178
publishDate 2016-01-01
description Background: Oral isotretinoin is highly effective in all forms and grades of acne, even in lower dosages (<0.5 mg/kg/day). There is a paucity of comparative data on the various low-dose regimens of oral isotretinoin in the Indian literature. Objectives: To assess and compare the efficacy and tolerability of two low-dose oral isotretinoin treatment regimens (20 mg daily and 20 mg alternate days) in moderate to severe acne vulgaris. Materials and Methods: A total of 240 patients with moderate to severe acne vulgaris were selected and randomized into two groups and treated with a fixed dose of 20 mg of isotretinoin (Group A - daily and Group B - alternate days) for 24 weeks and followed up for 12 weeks post therapy. Results: A total of 234 patients completed the study. At the end of therapy, decrease in the total acne loads up to 98.99% (Group A) and 97.69% (Group B) was achieved from the baseline (P < 0.01), excellent response was observed in 98.3% (Group A) and 93.96% (Group B) patients (P = 0.166). In the severe acne, Group A performed significantly better than Group B until the end of 36 weeks. While in the moderate acne, significant difference in the response between both groups was observed only up to 12 weeks. No serious side effect was observed. Conclusion: Both isotretinoin regimens were well tolerated and found to be an effective treatment for moderate to severe acne vulgaris. However, in moderate acne 20 mg alternate day regimen may be preferred. A 20 mg daily regimen is a better choice for severe acne in terms of response. Limitation: Small sample size and short follow-up period.
topic Acne vulgaris
fixed dose
low-dose isotretinoin
url http://www.idoj.in/article.asp?issn=2229-5178;year=2016;volume=7;issue=5;spage=378;epage=385;aulast=Dhaked
work_keys_str_mv AT daulatramdhaked arandomizedcomparativetrialoftwolowdoseoralisotretinoinregimensinmoderatetosevereacnevulgaris
AT ramsinghmeena arandomizedcomparativetrialoftwolowdoseoralisotretinoinregimensinmoderatetosevereacnevulgaris
AT anshulmaheshwari arandomizedcomparativetrialoftwolowdoseoralisotretinoinregimensinmoderatetosevereacnevulgaris
AT umashankaragarwal arandomizedcomparativetrialoftwolowdoseoralisotretinoinregimensinmoderatetosevereacnevulgaris
AT sarojpurohit arandomizedcomparativetrialoftwolowdoseoralisotretinoinregimensinmoderatetosevereacnevulgaris
AT daulatramdhaked randomizedcomparativetrialoftwolowdoseoralisotretinoinregimensinmoderatetosevereacnevulgaris
AT ramsinghmeena randomizedcomparativetrialoftwolowdoseoralisotretinoinregimensinmoderatetosevereacnevulgaris
AT anshulmaheshwari randomizedcomparativetrialoftwolowdoseoralisotretinoinregimensinmoderatetosevereacnevulgaris
AT umashankaragarwal randomizedcomparativetrialoftwolowdoseoralisotretinoinregimensinmoderatetosevereacnevulgaris
AT sarojpurohit randomizedcomparativetrialoftwolowdoseoralisotretinoinregimensinmoderatetosevereacnevulgaris
_version_ 1716763926231777280